New bladder cancer drug TARA-002 takes on chemotherapy in major trial
NCT ID NCT07480356
First seen Mar 22, 2026 · Last updated Apr 29, 2026 · Updated 7 times
Summary
This phase 3 trial tests whether the study drug TARA-002 works better than standard chemotherapy for adults with a high-grade, non-muscle invasive bladder cancer who have not received BCG therapy before. About 284 participants will be randomly assigned to receive either TARA-002 or chemotherapy directly into the bladder. The study will measure how many people have their cancer completely disappear and how long that effect lasts, while also tracking side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.